Physician profile
Mark Covington
NPI 1740201599
$4,972.12
in general payments reported to CMS, 2019-2025
23 companies · $323 in 2025
The $323 reported for 2025 was more than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,935 · 2020: $179 · 2021: $337 · 2022: $443 · 2023: $403 · 2024: $351 · 2025: $323.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,021 · Education: $56.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,021.04 |
| Education | $56.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intersect Ent, INC. | $2,699.07 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $527.59 | 2021-2025 | Dupixent |
| Glaxosmithkline, LLC. | $354.29 | 2021-2025 | Nucala |
| Aerin Medical INC. | $255.85 | 2019-2023 | |
| Genzyme Corporation | $221.15 | 2021-2024 | |
| Stryker Corporation | $193.47 | 2019-2023 | Xpress Ent Dilation System |
| Optinose US, INC. | $146.19 | 2019-2021 | |
| Smith+Nephew, INC. | $130.92 | 2022-2025 | Tula, Halo |
| Astrazeneca Pharmaceuticals LP | $87.87 | 2021-2025 | Tezspire |
| Novartis Pharmaceuticals Corporation | $43.00 | 2019-2024 | |
| Agiliti Surgical, INC. | $38.21 | 2019 | |
| Merck Sharp & Dohme LLC | $37.02 | 2021-2023 | |
| Acclarent, INC | $33.26 | 2019 | |
| Olympus America INC. | $29.73 | 2019 | |
| Genentech USA, INC. | $29.61 | 2023 | Xolair |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ambu INC. | $24.90 | 2024 | |
| Jazz Pharmaceuticals INC. | $21.62 | 2025 | |
| Davol INC. | $21.25 | 2021 | |
| Kaleo, INC. | $17.90 | 2023 | Auvi-Q |
| Janssen Biotech, INC. | $17.86 | 2025 | Tremfya |
| Medtronic, INC. | $15.25 | 2025 | Propel |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.27 | 2023 | Spiriva Respimat |
| Alk-Abello, INC | $11.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Covington listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.